Aptinyx, Inc.

Sage Therapeutics, Inc. already is on shaky ground with investors after Zurzuvae (zuranolone) was approved in the US last year for postpartum depression, but not for the larger indication of major de

AbbVie Inc. 's recent regulatory setback for a promising Parkinson's disease product has not skewed the US major's interest in the neurodegenerative disease, as the acquisition of Mitokinin, Inc. cl

Following the failure of its antibiotic ridinilazole in Clostridium difficile infection in December 2021, Summit Therapeutics plc executed a pivot from anti-infectives to oncology a year later whe

Aptinyx, Inc. ’s future is looking increasingly uncertain after it experienced yet another clinical trial failure. Its hopes in the neuropsychiatry space have died following a Phase II flop in Parkins